Long-term effects of busulphan on lymphocyte subpopulations in female B6C3F1 mice

Comparative Haematology International

Volumn 7, Issue 4, 1997, Pages 230-237

  Andrews, C M ^a   Dash, L M ^a,b   Williams, T C ^a   Craig Gray, J ^a   Turton, J A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Busulphan; Chloramphenicol succinate; Large unstained cells; Lymphocytopenia; Lymphocytosis; Mouse

Indexed keywords

BUSULFAN; CHLORAMPHENICOL HEMISUCCINATE; DRINKING WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; HEMATOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM EXPOSURE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOSIS; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; STAINING; T LYMPHOCYTE;

EID: 0031439220     PISSN: 09387714     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02658695     Document Type: Article

References (35)

1. Addison IE (1973) Immunosuppression with busulphan: the effect on spleen, marrow and thymus cells of mice. Eur J Immunol 3:419-424
2. Andrews CM, Spurling NW, Turton JA (1993) Characterisation of busulphan-induced myelotoxicity in B6C3F, mice using flow cytometry. Comp Haematol Int 3: 102-115
3. Beutler E, Lichtman MA, Coller BS et al. (eds) (1995) Williams' hematology, (5th edn). McGraw-Hill, New York
4. Bhoopalam N, Price KS, Norgello H et al. (1985) Busulfan-induced suppression of natural killer activity. Exp Hematol 13:1127-1132
5. Boggs DR, Boggs SS (1980) The effect of graded, single doses of busulfan on murine erythropoiesis. Proc Soc Exp Biol Med 163:181-186
6. Borella L, Green AA, Webster RG (1972) Immunologie rebound after cessation of long-term chemotherapy in acute leukaemia. Blood 40:42-51
7. Braun DP, Harris JE (1981) Modulation of the immune response by chemotherapy. Pharmacol Ther 14:89-122
8. Brohee D, Neve P, Vanhaeverbeek M et al. (1991) Is lymphopenia an obligatory side effect of all cancer chemotherapy treatments? Med Sei Res 19:801-802
9. den Ottolander GJ, te Velde J, Veenhof W et al. (1982) Busulphan aplasia in rabbits: a model for human aplastic anaemia. Br J Haematol 51: 265-276
10. Dünn CDR (1974) The chemical and biological properties of busulphan ('myeleran'). Exp Hematol 2:101-117
11. Elson LA (1955) A comparison of the effects of radiation and radiomimetic chemicals on the blood. Br J Haematol 1:104-116
12. Elson LA, Gallon DAG, Till M (1958) The action of chlorambucil and busulphan on the haemopoietic organs of the rat. Br J Haematol 4:355-374
13. Fitchen JH, Cline MJ (1980) The effect of granulopoietic stress in mice with 'latent' bone marrow failure. Exp Hematol 8:788-794
14. Gascon P, Zoumbous N, Young N (1986) Analysis of natural killer cells in patients with aplastic anaemia. Blood 67:1349-1355
15. Hall AG, Tilby MJ (1992) Mechanisms of actions of, and modes of resistance to, alkylating agents used in the 'treatment of haematological malignancies. Blood Rev 6:163-173
16. Irons RD, Stillman WS (1993) Cell proliferation and differentiation in chemical leukemogenesis. Stem Cells 11:235-242
17. Kato T, Ohta Y, Suzumura Y et al. (1988) Antitumour activity and neutrophil-selective hematopoietic toxicity of busulphan analogs in mice. Jpn J Cancer Res 79:1048-1053
18. Kinsey SE, Watts MJ (1988) Accurate automated leucocyte differential counts despite profound leucopenia. J Clin Pathol 41:1236-1239
19. Koza I, Babusikova O (1988) Sequential development of chronic lymphocytic leukaemia in a patient with polycythaemia vera. Neoplasma 35:77-80
20. Miale TD, Bloom GE (1975) The significance of lymphocytosis in congenital hypoplastic anemia. J Pediatr 87:550-553
21. Mitchell MS (1988) Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst 80:1445-1450
22. Morley A, Blake J (1974a) An animal model of chronic hypoplastic marrow failure. I. Late marrow failure after busulfan. Blood 44;49-56
23. Morley A, Blake J (1974b) Haemopoietic precursor cells in experimental hypolplastic marrow failure. Aust J Exp Biol Med Sei 52:909-914
24. Morley A, Holmes K, Forbes I (1974) Depletion of B lymphocytes in chronic hypoplastic marrow failure (aplastic anaermia). Aust NZ J Med 4:538-541
25. Morley A, Trainor K, Blake J (1975) A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 45:681-688
26. Morley A.Trainor K, Remes J (1976) Residual marrow damage: possible explanation for idiosyncrasy to chloramphenicol. Br J Haematol 32:525-531
27. Papayannis AG, Nikiforakis E, Aanagnostou-Keramida D (1982) Development of chronic lymphocytic leukaemia in a patient with polycythaemia vera. Scand J Haematol 29:65-69
28. Pugsley CAJ, Forbes IJ, Morley AA (1978) Immulogic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan. Blood 51:601-610
29. Robin E, Berman M, Bhoopalam N et al. (1981) Induction of lymphomas in mice by busulfan and chloramphenicol. Cancer Res 41:3478-3842
30. Sabbe LJM, Haak HL, Te Velde J et al. (1984) Immunlogical investigations in aplastic anaemia. Acta Haematol 71:178-188
31. Santos GW, Tutschka PJ (1974) Marrow transplantation in the busulfan-treated rat; preclinal model of aplastic anemia. J Natl Cancer Inst 53:1781-1785
32. Tonner E, Sewell HF, Thomson AW (1988) Cancer-induced alterations in T-cell subsets in normal and cyclophosphamide-treated mice. Int Arch Appl Immund 85:180-183
33. Vincent PC (1986) Drug-induced aplastic anaemia and agranulocytosis: incidence and mechanisms. Drugs 31:52-63
34. Wathen LM, DeGowin RL, Gibson P et al. (1982) Residual injury to the hemopoietic microenvironment following sequential radiation and busulfan. Int J Radiât Oncol Biol Phys 8:1315-1322
35. Yeager AM, Shinn C, Pardoll DM (1991) Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 78:12 3312-3316